Effect of LY2062430 on the Progression of Alzheimer’s Disease (EXPEDITION)
Effect of LY2062430 on the Progression of Alzheimer’s Disease (EXPEDITION2)
Alzheimer’s disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to complications of the disease. AD is thought to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase clearance, might be expected to slow the progression of AD. LY2062430 (solanezumab *USAN adopted name, INN pending) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1) monoclonal antibody being developed for the treatment of AD. The primary hypothesis being tested is that LY2062430 will slow cognitive and functional decline in AD as compared with placebo.
Each patient’s participation will last approximately 19 months. Patients taking approved AD medications may participate in this study and continue taking these medications during the study.
Contact: Eli Lilly
For additional information regarding investigative sites for this trial (locations), contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician.
EXPEDITION will be conducted in Argentina, Brazil, Canada, Japan, and United States. EXPEDITION 2 will be conducted in Australia, France, Germany, Italy, Japan, Korea, Poland, Russia, Spain, Sweden, Taiwan, United Kingdom, and United States.
Alzheimer’s Reading Room: Eli Lilly Launches Two Late Stage … – Eli Lilly and Company (NYSE: LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody … Effect of LY2062430 on the Progression of Alzheimer’s Disease (EXPEDITION) Effect of LY2062430 on the Progression of Alzheimer’s Disease (EXPEDITION2) Alzheimer’s disease (AD) is an age-related degenerative disorder of the brain, …
Eli Lilly Launches Two Global Trials For Alzheimer’s Disease … – Eli Lilly and Company is going to start enrolling patients for two separate but identical Phase III clinical trials of solanezumab(i), an anti-amyloid beta monoclonal antibody being researched as a possible treatment to delay the … The trials, termed as EXPEDITION and EXPEDITION 2, are identical multicenter, randomized, double-blind and placebo-controlled trials. Each will include a treatment period that lasts one and half year and are expected to enroll a total of 2000 …
Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into … – …INDIANAPOLIS May 21 /- Eli Lilly and Company (… …,Lilly,Advances,Second,Alzheimer’s,Disease,Treatment,Candidate,Into,Late-Stage,Testing,by,Launching,Two,Global,Trials,medicine,advanced medical technology,medical laboratory technology ,medical device technology,latest … The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2000 patients age 55 and over from 16 countries. …
Mike Havrilla on LLY – Eli Lilly and Company – SocialPicks – Eli Lilly (NYSE:LLY) : On 5/21/09, LLY announced that it will begin enrolling patients this month in two separate but identical Phase 3 clinical trials of solanezumab, which is an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the … The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2000 patients age 55 and over from 16 countries. …
Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into … – the EXPEDITION trials. The primary objective of both trials is to test whether solanezumab will slow the cognitive and functional decline of Alzheimer’s disease patients as compared with placebo. These outcomes will be analyzed … Eric Siemers M.D., Medical Director, Alzheimer’s disease research for Eli Lilly and Company. “Biomarker results from a Phase II solanezumab trial give us hope that Lilly is on a path toward a treatment that may slow the rate of …
Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into … – Eli Lilly and Company (NYSE: LLY) today announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody … Patients who are taking currently available symptomatic treatments for Alzheimer’s disease can continue treatment during their participation in the EXPEDITION trials. The primary objective of both trials is to test whether …
http://www.dimebonalzheimers.com
Related Websites - Basics of Alzheimer's Disease Alzheimer's disease is a frightening ailment that affects thousands of people every year. While studies are still being done to determine why exactly this disease hits, research is also being...
- Blood Test to Test for Early Signs of Alzheimers Disease Has a blood test for diagnosing Alzheimer's disease finally been discovered?Will it be possible to obtain an accurate diagnosis for Alzheimer's instead of the laborious and complicated diagnosis patients receive now?Keep...
- Moroccanoil Treatment - 3.4 oz. User Reviews Send this to a friend Moroccanoil Treatment - 3.4 oz. Manufacturer: Customer Rating: List Price: Varies based on product options Sale Price: View Sale Price Availibility: View Product...
- Video: StemCells Inc. using Neural Stem Cells for their Neuroprotective Effect Discover StemCells, Inc. A pioneer in the field of neural stem cells, StemCells Inc was founded by the renown Irving Weissman, Fred Gage, and David Anderson. Martin McGlynn, CEO, presents...
- PluristemBegins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease Pluristem Therapeutics Inc. today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company`s...
- Making Sure Your Corporate Blog Works For You Not Against You One of the main problems facing corporate bloggers is that their posts can be taken the wrong way, or controversy can get stirred up. Since one blog post has the...
- A Cure for Alzheimer's? Are we finally getting close to a cure for Alzheimer's? There is a lot of hope concerning the highly successful trials of the new drug Rember. The drug attacks the...